11,532 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Acquired by Vontobel Holding Ltd.

Vontobel Holding Ltd. bought a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,532 shares of the biopharmaceutical company's stock, valued at approximately $521,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp grew its stake in PTC Therapeutics by 5.4% in the third quarter. State Street Corp now owns 2,899,040 shares of the biopharmaceutical company's stock worth $107,554,000 after purchasing an additional 149,700 shares during the period. Geode Capital Management LLC grew its stake in PTC Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,798,666 shares of the biopharmaceutical company's stock worth $66,743,000 after purchasing an additional 10,886 shares during the period. Charles Schwab Investment Management Inc. grew its stake in PTC Therapeutics by 7.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 706,730 shares of the biopharmaceutical company's stock worth $26,220,000 after purchasing an additional 47,902 shares during the period. Point72 Asset Management L.P. grew its stake in PTC Therapeutics by 945.6% in the third quarter. Point72 Asset Management L.P. now owns 575,860 shares of the biopharmaceutical company's stock worth $21,364,000 after purchasing an additional 643,960 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in PTC Therapeutics by 32.1% in the third quarter. Assenagon Asset Management S.A. now owns 492,464 shares of the biopharmaceutical company's stock worth $18,270,000 after purchasing an additional 119,637 shares during the period.

Analyst Ratings Changes

Several brokerages recently weighed in on PTCT. Barclays upped their price target on PTC Therapeutics from $45.00 to $56.00 and gave the stock an "equal weight" rating in a research note on Tuesday, December 3rd. Citigroup increased their target price on PTC Therapeutics from $32.00 to $45.00 and gave the stock a "sell" rating in a research note on Wednesday, February 12th. Cantor Fitzgerald increased their target price on PTC Therapeutics from $76.00 to $113.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. The Goldman Sachs Group increased their target price on PTC Therapeutics from $32.00 to $42.00 and gave the stock a "sell" rating in a research note on Wednesday, December 4th. Finally, StockNews.com cut PTC Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $58.85.

PTC Therapeutics Trading Up 0.6 %

PTCT traded up $0.28 on Friday, hitting $50.66. 137,548 shares of the company's stock traded hands, compared to its average volume of 677,891. The company's 50 day simple moving average is $46.58 and its 200-day simple moving average is $41.35. The firm has a market cap of $3.91 billion, a price-to-earnings ratio of -8.53 and a beta of 0.62. PTC Therapeutics, Inc. has a one year low of $24.00 and a one year high of $54.16.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, insider Neil Gregory Almstead sold 69,550 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $52.06, for a total transaction of $3,620,773.00. Following the completion of the transaction, the insider now owns 86,202 shares in the company, valued at $4,487,676.12. This trade represents a 44.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Christine Marie Utter sold 17,800 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $51.77, for a total value of $921,506.00. Following the transaction, the chief accounting officer now owns 52,428 shares of the company's stock, valued at $2,714,197.56. This represents a 25.35 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 211,737 shares of company stock valued at $10,920,687. 5.50% of the stock is owned by company insiders.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.